Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03739-1 http://scihub22266oqcxt.onion/10.1038/s41586-021-03739-1 34192737!8373615!34192737     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 596 (7872): 417-422 Nephropedia Template TP {{tp|p=34192737|t=2021. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 |pdf=|usr=}}{{34192737}} gab.com Text Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=34192737 #FOAvip Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age(1). Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine(2) in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old. Sera from participants above eighty showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. (Gamma) VOC than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. The frequency of SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose serum showed neutralization activity) than in non-responders after the first dose. Elderly participants showed a clear reduction in somatic hypermutation of class-switched cells. The production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells was lower in older participants, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk population and that specific measures to boost vaccine responses in this population are warranted, particularly where variants of concern are circulating. Twit Text FOAVip Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=34192737 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34192737 #FOAvip English Wikipedia <ref>{{Cite pmid|34192737}}</ref> Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 #MMPMID34192737 Collier DA; Ferreira IATM; Kotagiri P; Datir RP; Lim EY; Touizer E; Meng B; Abdullahi A; Elmer A; Kingston N; Graves B; Le Gresley E; Caputo D; Bergamaschi L; Smith KGC; Bradley JR; Ceron-Gutierrez L; Cortes-Acevedo P; Barcenas-Morales G; Linterman MA; McCoy LE; Davis C; Thomson E; Lyons PA; McKinney E; Doffinger R; Wills M; Gupta RK Nature 2021[Aug]; 596 (7872): 417-422 PMID34192737show ga Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age(1). Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine(2) in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old. Sera from participants above eighty showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. (Gamma) VOC than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. The frequency of SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose serum showed neutralization activity) than in non-responders after the first dose. Elderly participants showed a clear reduction in somatic hypermutation of class-switched cells. The production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells was lower in older participants, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk population and that specific measures to boost vaccine responses in this population are warranted, particularly where variants of concern are circulating. |*Immunity/genetics[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Aging/blood/*immunology[MESH] |Antibodies, Neutralizing/blood/immunology[MESH] |Antibodies, Viral/blood/immunology[MESH] |Autoantibodies/immunology[MESH] |B-Lymphocytes/cytology/immunology/metabolism[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/administration & dosage/*immunology[MESH] |Female[MESH] |Health Personnel[MESH] |Humans[MESH] |Immunization, Secondary[MESH] |Immunoglobulin A/immunology[MESH] |Immunoglobulin Class Switching[MESH] |Immunoglobulin G/genetics/immunology[MESH] |Immunologic Memory/immunology[MESH] |Inflammation/blood/immunology[MESH] |Interferon-gamma/immunology[MESH] |Interleukin-2/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology[MESH] |Somatic Hypermutation, Immunoglobulin[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH] |T-Lymphocytes/immunology[MESH] |Vaccination[MESH] |Vaccines, Synthetic/administration & dosage/immunology[MESH]Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162(epmc).pdf DeepDyve Pubget Overpricing